Safety; PhamacokineticsSafety and Tolerability Endpoints- Adverse events that occurred after the initial dose of the study drug; including serious adverse events (SAEs)- Vital signs- Physical Findings- Laboratory Findings- 12-lead electrocardiographyEvaluation items for PK- Concentrations and PK parameters of casirivimab and imdevimab in Serum

Safety; PhamacokineticsSafety and Tolerability Endpoints- Adverse events that occurred after the initial dose of the study drug; including serious adverse events (SAEs)- Vital signs- Physical Findings- Laboratory Findings- 12-lead electrocardiographyEvaluation items for PK- Concentrations and PK parameters of casirivimab and imdevimab in Serum